Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of Combinatorial Pharmacogenomic Guidance in Treating Psychiatric Disorders:financial impact on a health plan

26 Sept 2018

Abstract excerpt

AIM: To evaluate payer costs associated with treating psychiatric disorders utilizing a combinatorial pharmacogenomics test versus treatment-as-usual (TAU). PATIENTS & METHODS: cohort) and those who received TAU (TAU cohort). Reimbursed costs were calculated over the 12-month pre-index and post-index event periods. RESULTS: 205 CPGx and 478 TAU members were included. Post-index cost savings (US$5505) drove a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pharmacogenetics and Drug Metabolism
Share to Phosphodiesterase function and regulation
Share to Schizophrenia research and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30256179
DOI: 10.2217/pme-2018-0074

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of Combinatorial Pharmacogenomic Guidance in Treating Psychiatric Disorders:financial impact on a health planPMID 30256179Read ↗

Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders.Semantic proximity Read ↗

Real-World Characterization of Psychiatric Pharmacogenomic Test Ordering and Clinical Relevance in Adults and Children.Semantic proximity Read ↗

Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?Semantic proximity Read ↗

Reimbursement of pharmacogenetic tests at a tertiary academic medical center in the United StatesSemantic proximity Read ↗

Diversity and level of evidence evaluation of commercial pharmacogenomic testing for mental healthSemantic proximity Read ↗

Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada.Semantic proximity Read ↗

Personalized medicine, pharmacogenomics, and the practice of psychiatry: on the threshold of predictive therapeutics in psychopharmacology?Semantic proximity Read ↗

Polypharmacy and pharmacogenomics in high-acuity behavioral health care for autism spectrum disorder: A retrospective studySemantic proximity Read ↗

Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial.Semantic proximity Read ↗

The Economics of Pharmacogenomics.Semantic proximity Read ↗

Pharmacogenetics and cost-effectiveness analysis: a two-way street.Semantic proximity Read ↗

Pharmacotherapy exposure as a marker of disease complexity in bipolar disorder: Associations with clinical & genetic risk factors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.